Geron Corp Reports Third Quarter 2026 Profitability Driven by RYTELO Growth

Geron Corporation (GERN) achieved its first profitable quarter since transitioning to a commercial-stage biopharmaceutical company, reporting net income of $1.4 million for Q3 2026. This turnaround was driven by a 27% year-over-year increase in net product revenue, totaling $60.1 million, and significant reductions in operating expenses following previous workforce optimizations. The company's RYTELO product saw steady adoption, with prescribing accounts growing to approximately 1,700. While the company issued positive full-year revenue guidance of $220 million to $240 million, it also noted the discontinuation of its Phase III IMpactMF trial due to an inability to meet primary endpoints regarding overall survival in relapsed/refractory myelofibrosis patients.

15 articles from 4 sources · updated

Coverage